BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38403687)

  • 1. Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora.
    Zhou L; Zheng L; Xu B; Ye Z; Li D; Wang W
    Orphanet J Rare Dis; 2024 Feb; 19(1):88. PubMed ID: 38403687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Metformin in Treatment of Adenomas in Patients with Familial Adenomatous Polyposis.
    Park JJ; Kim BC; Hong SP; Seo Y; Lee HS; Park YS; Na SY; Park SC; Park J; Kim JH; Moon CM; Huh KC; Park SJ; Cheon JH; Kim WH; Kim TI
    Cancer Prev Res (Phila); 2021 May; 14(5):563-572. PubMed ID: 33509804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis.
    Cruz-Correa M; Hylind LM; Marrero JH; Zahurak ML; Murray-Stewart T; Casero RA; Montgomery EA; Iacobuzio-Donahue C; Brosens LA; Offerhaus GJ; Umar A; Rodriguez LM; Giardiello FM
    Gastroenterology; 2018 Sep; 155(3):668-673. PubMed ID: 29802852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of Mesalazine in Familial Adenomatous Polyposis: Clinical Report of Reduction of Polyp Size in Patients with Ulcerative Colitis, and Safety Examination in Familial Adenomatous Polyposis Patients.
    Ishikawa H; Mutoh M; Abe T; Nakajima T; Takeuchi Y; Ezoe Y; Wakabayashi K; Doyama H; Sakai T
    Pharmacology; 2019; 104(1-2):51-56. PubMed ID: 31067545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
    Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
    Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
    Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
    Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Wholistic Turmeric Supplement on Adenomatous Polyps in Patients with Familial Adenomatous Polyposis-A Randomized, Double-Blinded, Placebo-Controlled Study.
    Gilad O; Rosner G; Ivancovsky-Wajcman D; Zur R; Rosin-Arbesfeld R; Gluck N; Strul H; Lehavi D; Rolfe V; Kariv R
    Genes (Basel); 2022 Nov; 13(12):. PubMed ID: 36553450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
    van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
    Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CHAMP-study: the CHemopreventive effect of lithium in familial AdenoMatous Polyposis; study protocol of a phase II trial.
    Linssen JDG; van Neerven SM; Aelvoet AS; Elbers CC; Vermeulen L; Dekker E
    BMC Gastroenterol; 2022 Aug; 22(1):383. PubMed ID: 35962368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial adenomatous polyposis.
    Half E; Bercovich D; Rozen P
    Orphanet J Rare Dis; 2009 Oct; 4():22. PubMed ID: 19822006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin combined with endoscopic therapy in patients with familial polyposis associated with carcinoma: A case report.
    Sun DJ; He XJ; Li HT; Luo BX; Zhou LX; Zeng XP; Li DZ; Wang W
    Medicine (Baltimore); 2022 Dec; 101(51):e32408. PubMed ID: 36595813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
    Samadder NJ; Foster N; McMurray RP; Burke CA; Stoffel E; Kanth P; Das R; Cruz-Correa M; Vilar E; Mankaney G; Buttar N; Thirumurthi S; Turgeon DK; Sossenheimer M; Westover M; Richmond E; Umar A; Della'Zanna G; Rodriguez LM; Szabo E; Zahrieh D; Limburg PJ
    Gut; 2023 Feb; 72(2):256-263. PubMed ID: 35636921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiome insights into pediatric familial adenomatous polyposis.
    Attard TM; Septer S; Lawson CE; Attard MI; Lee STM; Umar S
    Orphanet J Rare Dis; 2022 Nov; 17(1):416. PubMed ID: 36376984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, placebo-controlled trial of gastric acid-lowering therapy on duodenal polyposis and relative adduct labeling in familial adenomatous polyposis.
    Wallace MH; Forbes A; Beveridge IG; Spigelman AD; Hewer A; Venitt S; Phillips RK
    Dis Colon Rectum; 2001 Nov; 44(11):1585-9. PubMed ID: 11711728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients.
    Sample DC; Samadder NJ; Pappas LM; Boucher KM; Samowitz WS; Berry T; Westover M; Nathan D; Kanth P; Byrne KR; Burt RW; Neklason DW
    BMC Gastroenterol; 2018 Jul; 18(1):115. PubMed ID: 30012100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer in Patients With Familial Adenomatous Polyposis: A Nationwide Danish Cohort Study With Matched Controls.
    Karstensen JG; Bülow S; Højen H; Jelsig AM; Jespersen N; Andersen KK; Wewer MD; Burisch J; Pommergaard HC
    Gastroenterology; 2023 Sep; 165(3):573-581.e3. PubMed ID: 37201686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
    Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
    Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.